Eradication of hepatic metastases of carcinoma H-59 by combination chemoimmunotherapy with liposomal muramyl tripeptide, 5-fluorouracil, and leucovorin - PubMed (original) (raw)

. 1992 Nov 15;52(22):6254-7.

Affiliations

PMID: 1423270

Eradication of hepatic metastases of carcinoma H-59 by combination chemoimmunotherapy with liposomal muramyl tripeptide, 5-fluorouracil, and leucovorin

T Asao et al. Cancer Res. 1992.

Abstract

We have investigated the effect of a combined chemoimmunotherapy protocol with liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE), 5-fluorouracil (5-FU), and 5-formyltetrahydrofolate (leucovorin) on the growth of hepatic metastases using carcinoma H-59, a liver-homing subline of the Lewis lung carcinoma (P. Brodt, Cancer Res., 46: 2442-2448, 1986). C57BL/6 mice inoculated with the tumor cells via the intrasplenic route received three i.v. injections of liposomal MTP-PE, the first of which was administered 3 days prior to tumor cell inoculation. Chemotherapy with 5-FU and leucovorin at the maximal tolerated doses (30 mg/kg per injection) was initiated immediately after tumor inoculation and continued on alternate days for a total of 4 injections. The incidence of liver metastases in animals which received the combined therapy was compared to that in animals treated with chemotherapy or immunotherapy alone. We found that while the number of liver metastases was reduced in all of the treatment groups as compared to control untreated or placebo-treated animals, the combined effect of 5-FU leucovorin and liposomal MTP-PE was significantly better than that of chemotherapy or immunotherapy alone. This was reflected in a reduced incidence (70% as compared to 100% in all other groups) and in a significant reduction in the number and size of the liver nodules. Our results suggest that the efficacy of 5-FU and leucovorin in the treatment of hepatic metastases could be significantly augmented by the addition of the liposome-encapsulated immunoadjuvant MTP-PE.

PubMed Disclaimer

Cited by

Inhibition of carcinoma cell invasion and liver metastases formation by the cysteine proteinase inhibitor E-64.
Navab R, Mort JS, Brodt P. Navab R, et al. Clin Exp Metastasis. 1997 Mar;15(2):121-9. doi: 10.1023/a:1018496625936. Clin Exp Metastasis. 1997. PMID: 9062388
The anticancer immune response: indispensable for therapeutic success?
Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. Zitvogel L, et al. J Clin Invest. 2008 Jun;118(6):1991-2001. doi: 10.1172/JCI35180. J Clin Invest. 2008. PMID: 18523649 Free PMC article. Review.
Combination therapy with a synthetic peptide of C-reactive protein and interleukin 2: augmented survival and eradication of pulmonary metastases.
Barna BP, Thomassen MJ, Maier M, Medendorp SV, Tubbs RR, Chiang T, Zhou P, Yen-Lieberman B, Singh-Burgess S, Deodhar SD. Barna BP, et al. Cancer Immunol Immunother. 1994 Jan;38(1):38-42. doi: 10.1007/BF01517168. Cancer Immunol Immunother. 1994. PMID: 8299117 Free PMC article.
Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis.
Khatib AM, Auguste P, Fallavollita L, Wang N, Samani A, Kontogiannea M, Meterissian S, Brodt P. Khatib AM, et al. Am J Pathol. 2005 Sep;167(3):749-59. doi: 10.1016/S0002-9440(10)62048-2. Am J Pathol. 2005. PMID: 16127154 Free PMC article.
Antitumor activity of 5-fluorouracil polymeric nanogel synthesized by gamma radiation on a rat model of colon carcinoma: a proposed mechanism.
Abo-Zaid OAR, Moawed FSM, Barakat WEM, Ghobashy MM, Ahmed ESA. Abo-Zaid OAR, et al. Discov Oncol. 2023 Jul 26;14(1):138. doi: 10.1007/s12672-023-00733-z. Discov Oncol. 2023. PMID: 37493814 Free PMC article.

Eradication of hepatic metastases of carcinoma H-59 by combination chemoimmunotherapy with liposomal muramyl tripeptide, 5-fluorouracil, and leucovorin - PubMed (original) (raw)